Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment

References

• Buzdar A, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature Phase III trials. Cancer 83, 1142–1152 (1998).
   PubMed Web of Science ®Google Scholar
• ••This combined analysis of two trials of postmenopausal patients with advanced breast carcinoma has clearly demonstrated that, after disease progression with tamoxifen, treatment with anastrozole 1 mg once daily results in a statistically and clinically significant advantage over a standard treatment, megestrol acetate.
   Google Scholar
• Dombernowsky P Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.' Clin. Oncol. 16, 453–461(1998).
   Google Scholar
• ••Demonstrates the clinical superiority ofthe third-generation aromatase inhibitor letrozole over megestrol acetate, with a superior safety profile.
   Google Scholar
• Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial." Gun. Onca 18(7), 1399–1411 (2000).
   Google Scholar
• ••Compares exemestane with megestrolacetate; time to disease progression, time to treatment failure and overall survival were all significantly better for exemestane than megestrol acetate.
   Google Scholar
• Mouridsen H, Sun Y, Gershanovich M et al Final survival analysis of the double-blind, randomised, multinational Phase III trial of letrozole (Femaralm) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2001).
   Google Scholar
• ••Supports the use of letrozole as first-lineendocrine therapy in postmenopausal women with advanced breast cancer.
   Google Scholar
• Baum M, on behalf of the ATAC trialists' Group. The ATAC (Arimidex, Tammdfen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. 24th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA (2001).
   Google Scholar
• ••Landmark results from the single largestadjuvant trial ever conducted in postmenopausal patients with early breast cancer.
   Google Scholar
• Miller WR, Dixon JM. Anti-aromatase agents: preclinical data and neoadjuvant therapy. Clin. Breast Cancer l(Suppl. 1), S9—S14 (2000).
   Google Scholar
• •Highlights that the ability to block estrogen biosynthesis peripherally and locally within the breast provides new options for the treatment of hormone-sensitive breast cancers in postmenopausal women.
   Google Scholar
• Johnston SR Acquired tamoxifen resistance: potential mechanisms and clinical implications. Anti Cancer Drugs 8, 911–930 (1997).
   PubMedGoogle Scholar
• Dowsett M, Jones A, Johnston SRD et al.In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clin. Cancer Res. 1, 1511–1515 (1995).
   Google Scholar
• Geisler J, King N, Dowsett Metal.Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 74,1286–1291 (1996).
   Google Scholar
• Geisler J, King N, Anker G etal. In vivo inhibition of amortisation by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res. 4,2089–2093 (1998).
   Google Scholar
• ••The first study to reveal near totalaromatase inhibition in vivo with the use of a steroidal aromatase inhibitor and to identify exemestane as a promising new drug for the treatment of hormone-sensitive breast cancer.
   Google Scholar
• Geisler J, Haynes B, Anker G et at Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study." Clin. Onca 20(3), 751–757 (2002).
   Google Scholar
• •This study compared the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels. Letrozole was found to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozole in postmenopausal women with metastatic breast cancer.
   Google Scholar
• Chen S, Zhou D, Okubo T et at Breast tumor aromatase: functional role and transcriptional regulation. Endocr. Relat. Cancer 6,149–156 (1999).
   PubMed Web of Science ®Google Scholar
• Harada N, Honda SI, Hatano O. Aromatase inhibitors and enzyme stability. Endocr. Relat. Cancer 6,211–218 (1999).
   PubMed Web of Science ®Google Scholar
• Poggesi I, Jannuzzo MG, di-Salle E et al. Effect of food and formulation on the pharmacokinetics (PK) and pharmacodynarnics (PD) of a single oral dose of exemestane (Aromasinim, EXE). Proc. Am. Soc. Clin. Oncol. 18,193a (1999) (Abstract 741).
   Google Scholar
• Johannessen DC, Engan T, di-Salle E et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a Phase I study. Clin. Cancer Res. 3,1101-1108 (1997).
   Google Scholar
• Paridaens R, Thomas J, Wildiers J et al. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a Phase I study. Anticancer Drugs 9,675–683 (1998).
   PubMed Web of Science ®Google Scholar
• Kvinnsland S, Anker G, Dirix L-Y et al. Activity of exemestane, an irreversible, oral, aromatase inhibitor in metastatic postmenopausal breast cancer patients (MBQ failing tamoxifen (TAM). Eur. Cancer 34, S91\(Suppl. 5) (1998) (Abstract 408).
   Google Scholar
• Jones S, Belt R, Cooper B et al A Phase II study of antitumor efficacy and safety of exemestane (EXE) as second-line hormonal treatment of postmenopausal patients with metastatic breast cancer (MBC) refractory to tamoxifen (Tam). Breast Cancer Res. Treat. 50,304 (1998) (Abstract 436).
   Google Scholar
• Thiirlimann B, Paridaens R, Serin D et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on arninoglutethimide: a Phase II multicentre multinational study. Eur. j Cancer 33, 1767–1773 (1997).
   PubMedGoogle Scholar
• Jones S, Vogel C, Arkhipov A et al. Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J. Clin. Oncol. 17,3418–3425 (1999).
   PubMed Web of Science ®Google Scholar
• Lanning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial." Clin. Oncol. 18(11), 2234–2244 (2000).
   Google Scholar
• •Paper highlights a lack of cross-resistance between steroidal and nonsteroidal aromatase inhibitors, which may provide the option for their use sequentially in advanced breast cancer at the time of progression.
   Google Scholar
• Paridaens R, Dirix L, Beex L et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized Phase II EORTC trial with a tamoxifen control. Clin. Breast Cancer 1(1), S19—S21 (2000).
   Google Scholar
• Dirix L, Piocart MJ, Lohrish C et al Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in first-line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBQ patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia 8c Upjohn. Proc. Am. Soc. Clin. OncoZ 20,29a (2001).
   Google Scholar
• Key TJ. Serum oestradiol and breast cancer risk Endocn Relat. Cancer 6,175–180 (1999).
   Google Scholar
• Clemons M, Goss P Mechanisms of disease: estrogen and the risk of breast cancer. N EngZ J. Med. 344,276–285(2001).
   PubMed Web of Science ®Google Scholar
• Kvinnsland S, Anker G, Dirix LY et id High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tammdfen treatment. Eur. Cancer 36(8), 976–982(2000).
   PubMedGoogle Scholar
• Tedeschi M, Kvinnsland S, Jones SE et al. Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasinim (Exemestane), in advanced breast cancer patients having progressed on anti-estrogens. In: Proceedings of European Cancer Conference, Vienna, Austria, (1999) (Abstract).
   Google Scholar
• Santen RJ, Yue W, Naftolin F et al. The potential of aromatase inhibitors in breast cancer prevention. Endocn Relat. Cancer 6, 235–243 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher B, Constantino JR Wickerham DL et id Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. 1Vad Cancer Inst. 90,1371-1388 (1998).
   Google Scholar
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352,930–942 (1998).
   PubMedGoogle Scholar
• ••Provides an updated review of the results ofthe many randomized trials of adjuvant prolonged polychernotherapy among women with early breast cancer. It demonstrates clear evidence of benefit in support of polychemotherapy and shows that some months of adjuvant polychemotherapy (such as CIVIF or some anthracycline-containing regimen) can produce substantial reductions in recurrence and mortality in women with early breast cancer up to at least 70 years of age.
   Google Scholar
• Cummings SR, Eckert S, Krueger KA et al. The effect of ralmdfene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Ralmdfene Evaluation. JANIA 281, 2189–2197 (1999).
   Google Scholar
• Goss PE, Strasser K Aromatase inhibitors in the treatment and prevention of breast cancer. Clin. Oncoll9(3), 881–894(2001).
   Google Scholar
• ••Insight into chemopreventive strategies.Provides an overview of the current clinical status and possible future applications of aromatase inhibitors in breast cancer.
   Google Scholar
• Lonning PE. Aromatase inhibitors and inactivators in breast cancer. BMJ 323, 880–881 (2001).
   PubMedGoogle Scholar
• ••Excellent editorial providing a succinct summary on the role of these potent inhibitors of estrogen synthesis.
   Google Scholar
• Harper-Wynne C, Ross G, Sacks N, Dowsett M. A pilot prevention study of the aromatase inhibitor letrozole: effects on breast cell proliferation and bone/lipid indices in healthy postmenopausal women. 24th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA (2001).
   Google Scholar
• Goss P, Grynpas M, Qi S, Hu H. The effects of exemestane on bone and lipids in the ovariectoinized rat. 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA (2001).
   Google Scholar